The VIRAGE2 trial is a small 6-patient feasibility study, not a pivotal efficacy trial — de-risking the dosing regimen for a future Phase 3 is a positive but early step. Monitor for enrollment updates and any interim safety data; the stock's $12M market cap means binary trial risk remains high. No financial data or guidance was provided, so the near-term catalyst is purely clinical.
Price Chart
Executive Summary
Theriva Biologics received regulatory authorization from the Spanish AEMPS to initiate the VIRAGE2 Phase 2a clinical trial, a 6-patient proof-of-concept study evaluating more frequent dosing (at least 3 doses) of oncolytic adenovirus VCN-01 in first-line metastatic pancreatic cancer. The trial builds on prior VIRAGE Phase 2b data where 2-dose VCN-01 showed significantly improved overall survival, progression-free survival, and duration of response versus 1-dose or chemotherapy alone. This is an early exploratory step toward a potential pivotal Phase 3 trial, but no financial data, guidance, or near-term revenue catalyst is provided.
Key Facts
- Spanish AEMPS authorized initiation of VIRAGE2 Phase 2a trial for VCN-01 in first-line metastatic pancreatic cancer
- VIRAGE2 is a 6-patient, single-arm, open-label, proof-of-concept trial evaluating at least 3 doses of VCN-01 given 2 months apart with gemcitabine/nab-paclitaxel
- Prior VIRAGE Phase 2b (112 patients) showed 2-dose VCN-01 significantly improved overall survival, progression-free survival, and duration of response vs 1-dose or chemotherapy alone
- EMA and FDA recognized improved survival with 2-dose VCN-01 and suggested more frequent dosing could improve outcomes
- VIRAGE2 results will inform dosing regimen for a potential future pivotal Phase 3 trial
- No financial data, guidance, or revenue figures were provided in this filing
Financial Impact
No financial data or guidance provided; this is a clinical trial authorization with no revenue or cost figures disclosed
Risk Factors
- VIRAGE2 is a 6-patient single-arm study not powered for efficacy — positive safety/tolerability data is needed before a Phase 3 can be designed
- Company has a $12M market cap with no disclosed revenue or financing; clinical-stage biotech carries high dilution and cash-burn risk
- Prior TOVX reports show high volatility with mixed T+20 outcomes (50% win rate, +6.31% avg P&L but with large negative outliers)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-080962 |
| Document: tm2619846d1_ex99-1.htm | 0001104659-26-080962 |
| Document: 0001104659-26-080962-index-headers.html | 0001104659-26-080962 |
| Document: 0001104659-26-080962-index.html | 0001104659-26-080962 |
| Document: 0001104659-26-080962.txt | 0001104659-26-080962 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $0.2300 $0.2490 | ▲ +8.26% | ▲ +9.32% | $0.2306 (+0.26%) |
Aug 11, 2026 7w ago | Press Release | $0.2300 $0.2490 | ▲ +8.26% | ▲ +9.32% | $0.2306 (+0.26%) |
Aug 4, 2026 8w ago | 8-K | $0.2300 $0.2490 | ▼ −8.26% | ▼ −9.50% | $0.2306 (−0.26%) |
Jul 7, 2026 12w ago | 8-K | $0.2354 $0.2227 | ▼ −5.40% | ▼ −6.73% | $0.2306 (−2.04%) |
Jun 11, 2026 16w ago | Press Release | $0.3070 $0.2345 | ▼ −23.62% | ▼ −25.51% | $0.2306 (−24.89%) |
Apr 17, 2026 23w ago | 8-K | $0.4100 $0.3000 | ▼ −26.83% | ▼ −31.03% | $0.2306 (−43.76%) |
Mar 12, 2026 29w ago | 8-K | $0.1800 $0.2300 | ▲ +27.78% | ▲ +25.80% | $0.2306 (+28.11%) |
Mar 12, 2026 29w ago | Press Release | $0.1800 $0.2300 | ▲ +27.78% | ▲ +25.80% | $0.2306 (+28.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access